[go: up one dir, main page]

MX354125B - Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. - Google Patents

Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.

Info

Publication number
MX354125B
MX354125B MX2013007622A MX2013007622A MX354125B MX 354125 B MX354125 B MX 354125B MX 2013007622 A MX2013007622 A MX 2013007622A MX 2013007622 A MX2013007622 A MX 2013007622A MX 354125 B MX354125 B MX 354125B
Authority
MX
Mexico
Prior art keywords
opioid
parkinson
disease
treatment
combination
Prior art date
Application number
MX2013007622A
Other languages
English (en)
Other versions
MX2013007622A (es
Inventor
Michael Hopp
Claudia Trenkwalder
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354125(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2013007622A publication Critical patent/MX2013007622A/es
Publication of MX354125B publication Critical patent/MX354125B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una forma de dosificación farmacéutica que comprende un agonista opioide y un antagonista opioide para su uso en el tratamiento de la enfermedad de Parkinson. La presente invención también se refiere al uso de un agonista opioide y un antagonista opioide en dicha forma de dosificación.
MX2013007622A 2010-12-28 2011-12-27 Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. MX354125B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10197210 2010-12-28
PCT/EP2011/074103 WO2012089738A1 (en) 2010-12-28 2011-12-27 A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
MX2013007622A MX2013007622A (es) 2013-12-06
MX354125B true MX354125B (es) 2018-02-14

Family

ID=43903970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007622A MX354125B (es) 2010-12-28 2011-12-27 Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.

Country Status (20)

Country Link
US (1) US20140037729A1 (es)
EP (1) EP2658523A1 (es)
JP (2) JP5864606B2 (es)
KR (2) KR101632858B1 (es)
CN (1) CN103347495B (es)
AR (1) AR084620A1 (es)
AU (1) AU2011351447B2 (es)
BR (1) BR112013016862A2 (es)
CA (1) CA2822528C (es)
CL (1) CL2013001943A1 (es)
EA (1) EA025747B1 (es)
MX (1) MX354125B (es)
MY (1) MY162895A (es)
NZ (1) NZ612837A (es)
PH (1) PH12013501244A1 (es)
SG (1) SG191208A1 (es)
TW (2) TW201628618A (es)
UA (1) UA109301C2 (es)
WO (1) WO2012089738A1 (es)
ZA (1) ZA201304303B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344846B (es) 2010-05-10 2017-01-10 Euro-Celtique S A * Combinacion de granulos cargados activos con activos adicionales.
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
SG191208A1 (en) * 2010-12-28 2013-07-31 Euro Celtique Sa A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
EP2701707B1 (en) 2011-04-29 2020-09-02 Rutgers, the State University of New Jersey Method of treating dyskinesia
US10736889B2 (en) 2011-04-29 2020-08-11 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US9918980B2 (en) 2011-04-29 2018-03-20 Rutgers, The State University Of New Jersey Method of treating dyskinesia
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
JP2016525138A (ja) * 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
US20150352099A1 (en) * 2014-06-04 2015-12-10 Mentinova Inc. Compositions and Methods of Reducing Sedation
US9765027B2 (en) 2014-08-22 2017-09-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
CA2974055A1 (en) * 2015-01-23 2016-07-28 Euro-Celtique S.A. A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk forintestinal bacterial translocation
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
AU2016266432B2 (en) * 2015-05-26 2020-10-22 Laboratorio Medinfar-Produtos Farmacêuticos, S.A. Compositions for use in treating Parkinson's disease and related disorders
WO2018055199A1 (en) * 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
MX2022001520A (es) * 2019-08-11 2022-07-21 Kappa Pharma Llc Composiciones y metodos para mejorar activacion de receptor de opioide por hexadienoatos opioides y hexadienoatos opcionalmente sustituidos.
US20230343429A1 (en) * 2019-10-31 2023-10-26 The United States Government As Represented By The Department Of Veterans Affairs Methods, systems, and apparatus for tapering or uptitrating drug dosages
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
DE60138706D1 (de) * 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
CA2386794A1 (en) * 2000-07-13 2002-01-24 Euro-Celtique, S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US20070232638A1 (en) * 2006-04-03 2007-10-04 Howard Brooks-Korn Opiopathies
WO2009132313A2 (en) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
BRPI1006186A2 (pt) * 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
SG191208A1 (en) * 2010-12-28 2013-07-31 Euro Celtique Sa A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease

Also Published As

Publication number Publication date
NZ612837A (en) 2014-11-28
KR101632858B1 (ko) 2016-06-22
PH12013501244A1 (en) 2013-07-15
JP2014501268A (ja) 2014-01-20
CL2013001943A1 (es) 2013-11-29
SG191208A1 (en) 2013-07-31
JP2016040268A (ja) 2016-03-24
BR112013016862A2 (pt) 2016-10-04
AU2011351447A1 (en) 2013-07-25
MY162895A (en) 2017-07-31
UA109301C2 (uk) 2015-08-10
TW201302199A (zh) 2013-01-16
CN103347495A (zh) 2013-10-09
KR20150076262A (ko) 2015-07-06
EP2658523A1 (en) 2013-11-06
WO2012089738A1 (en) 2012-07-05
MX2013007622A (es) 2013-12-06
AU2011351447B2 (en) 2016-02-25
JP5864606B2 (ja) 2016-02-17
AR084620A1 (es) 2013-05-29
EA201390977A1 (ru) 2013-12-30
KR101618929B1 (ko) 2016-05-09
JP6074003B2 (ja) 2017-02-01
TWI554271B (zh) 2016-10-21
CA2822528C (en) 2017-07-18
CN103347495B (zh) 2017-06-20
KR20130106431A (ko) 2013-09-27
CA2822528A1 (en) 2012-07-05
ZA201304303B (en) 2014-02-26
US20140037729A1 (en) 2014-02-06
TW201628618A (zh) 2016-08-16
EA025747B1 (ru) 2017-01-30

Similar Documents

Publication Publication Date Title
MX354125B (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
PE20141171A1 (es) Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
CL2012000702A1 (es) Uso de un agonista del receptor de acetilcolina nicotinico alfa-7 para el tratamiento de la discinesia asociada a la terapia con agonista de dopamina en la enfermedad de parkinson.
CL2014001450A1 (es) Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2008000418A1 (es) Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica.
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
MX348933B (es) Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico.
UY31922A (es) Compuestos
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
EA202091356A1 (ru) A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
CR20120461A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
DOP2010000361A (es) Dronedarona para la prevencion de la cardioversion
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.

Legal Events

Date Code Title Description
FG Grant or registration